Insmed (INSM) Proxy filing summary

Executive summary

• Achieved FDA and European Commission approval for BRINSUPRI (brensocatib) for NCFB and reported $172.7M in first-year revenues.

• ARIKAYCE revenues reached $433.8M in 2025, exceeding guidance, with 19% global growth year-over-year.

• Positive topline data from Phase 2b TPIP study in PAH; initiated Phase 3 studies in PH-ILD and continued pipeline expansion.

• Workforce grew to nearly 1,700 employees; recognized as a top employer for the fifth consecutive year.

• Stock price increased over 150% in 2025, reflecting strong shareholder value creation.

Voting matters and shareholder proposals

• Election of two Class II directors, Elizabeth McKee Anderson and Clarissa Desjardins, Ph.D., to serve until 2029.

• Advisory vote on 2025 compensation of named executive officers.

• Ratification of Ernst & Young LLP as independent registered public accounting firm for 2026.

• Shareholder proposals for the 2027 meeting must be submitted by December 2, 2026.

Board of directors and corporate governance

• Board consists of eight members, seven of whom are independent; includes three women and two minorities.

• Board committees: Audit, Compensation, Nominations and Governance, Science and Technology—all members independent.

• Annual board and committee self-evaluations; third-party facilitator used in 2024.

• Stock ownership guidelines for directors and executives increased in 2025.

• No dual-class stock; annual advisory vote on executive compensation.